 Virginia Borges
Concepts (582)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 138 | 2025 | 2253 | 12.530 |
Why?
| | Receptor, ErbB-2 | 30 | 2025 | 341 | 3.080 |
Why?
| | Pregnancy Complications, Neoplastic | 14 | 2021 | 52 | 3.040 |
Why?
| | Postpartum Period | 19 | 2024 | 340 | 2.780 |
Why?
| | Cancer Survivors | 17 | 2024 | 285 | 2.170 |
Why?
| | Receptors, Estrogen | 21 | 2025 | 436 | 2.080 |
Why?
| | Antineoplastic Agents, Hormonal | 14 | 2025 | 161 | 2.000 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 20 | 2025 | 1692 | 1.950 |
Why?
| | Carcinoma, Ductal, Breast | 10 | 2023 | 83 | 1.790 |
Why?
| | Mastectomy | 17 | 2024 | 137 | 1.740 |
Why?
| | Protein Kinase Inhibitors | 7 | 2025 | 916 | 1.520 |
Why?
| | Lactation | 9 | 2021 | 181 | 1.300 |
Why?
| | Female | 156 | 2025 | 73304 | 1.180 |
Why?
| | Brain Neoplasms | 10 | 2025 | 1238 | 1.170 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 7 | 2023 | 56 | 1.160 |
Why?
| | Neoplasm Metastasis | 13 | 2025 | 658 | 1.110 |
Why?
| | Breast | 10 | 2021 | 151 | 1.060 |
Why?
| | Triple Negative Breast Neoplasms | 7 | 2025 | 202 | 1.000 |
Why?
| | Adult | 93 | 2025 | 37929 | 0.970 |
Why?
| | Antineoplastic Agents | 12 | 2023 | 2129 | 0.960 |
Why?
| | Trastuzumab | 13 | 2023 | 96 | 0.950 |
Why?
| | Receptors, Progesterone | 7 | 2025 | 350 | 0.940 |
Why?
| | Pregnancy | 34 | 2025 | 6763 | 0.900 |
Why?
| | Mammary Glands, Human | 7 | 2020 | 64 | 0.870 |
Why?
| | Humans | 165 | 2025 | 137585 | 0.870 |
Why?
| | Supreme Court Decisions | 1 | 2022 | 11 | 0.790 |
Why?
| | Mammary Glands, Animal | 9 | 2021 | 129 | 0.730 |
Why?
| | BRCA2 Protein | 5 | 2024 | 63 | 0.710 |
Why?
| | Carcinoma | 3 | 2021 | 240 | 0.700 |
Why?
| | Pyridines | 6 | 2025 | 506 | 0.690 |
Why?
| | Semaphorins | 4 | 2025 | 32 | 0.690 |
Why?
| | Fertility Preservation | 7 | 2025 | 49 | 0.690 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2020 | 34 | 0.690 |
Why?
| | Oxazoles | 5 | 2025 | 37 | 0.670 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2022 | 801 | 0.650 |
Why?
| | Breast Feeding | 6 | 2025 | 440 | 0.640 |
Why?
| | Maternal Age | 1 | 2020 | 129 | 0.640 |
Why?
| | Neoadjuvant Therapy | 6 | 2021 | 404 | 0.640 |
Why?
| | Antigens, CD | 6 | 2025 | 521 | 0.630 |
Why?
| | Middle Aged | 56 | 2025 | 33479 | 0.620 |
Why?
| | Quinazolines | 5 | 2025 | 251 | 0.600 |
Why?
| | Prospective Studies | 32 | 2025 | 7604 | 0.600 |
Why?
| | Estradiol | 5 | 2019 | 521 | 0.590 |
Why?
| | Extracellular Vesicles | 1 | 2020 | 146 | 0.580 |
Why?
| | Prognosis | 15 | 2022 | 4030 | 0.560 |
Why?
| | Carcinoma in Situ | 3 | 2022 | 49 | 0.560 |
Why?
| | Young Adult | 37 | 2024 | 13209 | 0.560 |
Why?
| | Parity | 7 | 2022 | 126 | 0.550 |
Why?
| | Neoplasm Recurrence, Local | 13 | 2023 | 1079 | 0.540 |
Why?
| | Lymphatic Metastasis | 10 | 2021 | 352 | 0.530 |
Why?
| | Neoplasm Staging | 17 | 2022 | 1389 | 0.530 |
Why?
| | Neoplasms, Second Primary | 3 | 2024 | 118 | 0.520 |
Why?
| | Chemotherapy, Adjuvant | 14 | 2025 | 389 | 0.510 |
Why?
| | Quality of Life | 11 | 2024 | 2892 | 0.510 |
Why?
| | Cyclooxygenase 2 | 5 | 2020 | 178 | 0.490 |
Why?
| | Mutation | 11 | 2025 | 3958 | 0.450 |
Why?
| | Capecitabine | 5 | 2023 | 45 | 0.450 |
Why?
| | Aromatase Inhibitors | 6 | 2019 | 54 | 0.450 |
Why?
| | Liver Neoplasms | 4 | 2016 | 786 | 0.440 |
Why?
| | Carcinoma, Lobular | 2 | 2012 | 49 | 0.440 |
Why?
| | Melanoma | 4 | 2018 | 760 | 0.430 |
Why?
| | Mastectomy, Segmental | 6 | 2022 | 93 | 0.430 |
Why?
| | Skin Neoplasms | 4 | 2013 | 855 | 0.420 |
Why?
| | Combined Modality Therapy | 10 | 2023 | 1236 | 0.420 |
Why?
| | Puerperal Disorders | 2 | 2014 | 31 | 0.410 |
Why?
| | BRCA1 Protein | 4 | 2024 | 76 | 0.400 |
Why?
| | Stromal Cells | 3 | 2013 | 112 | 0.380 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2021 | 528 | 0.370 |
Why?
| | Anxiety | 7 | 2022 | 1035 | 0.370 |
Why?
| | Biomarkers, Tumor | 10 | 2023 | 1276 | 0.360 |
Why?
| | Sexual Partners | 3 | 2022 | 186 | 0.350 |
Why?
| | Nevus, Pigmented | 1 | 2011 | 34 | 0.350 |
Why?
| | Epithelial Cells | 6 | 2018 | 1096 | 0.350 |
Why?
| | Disease-Free Survival | 7 | 2023 | 686 | 0.340 |
Why?
| | Neoplasm Invasiveness | 6 | 2020 | 510 | 0.340 |
Why?
| | Fertility | 5 | 2025 | 160 | 0.330 |
Why?
| | Radiosurgery | 3 | 2021 | 344 | 0.330 |
Why?
| | Tamoxifen | 7 | 2021 | 202 | 0.320 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2025 | 804 | 0.320 |
Why?
| | Cyclophosphamide | 5 | 2020 | 247 | 0.320 |
Why?
| | Estrogens | 4 | 2015 | 367 | 0.320 |
Why?
| | Adjuvants, Immunologic | 2 | 2022 | 226 | 0.310 |
Why?
| | Gene Expression Profiling | 8 | 2020 | 1774 | 0.300 |
Why?
| | Risk Factors | 17 | 2024 | 10388 | 0.300 |
Why?
| | Thrombophilia | 1 | 2009 | 83 | 0.300 |
Why?
| | Aged | 28 | 2025 | 23961 | 0.300 |
Why?
| | GPI-Linked Proteins | 4 | 2025 | 73 | 0.300 |
Why?
| | T-Lymphocytes | 6 | 2018 | 1996 | 0.300 |
Why?
| | Incidence | 7 | 2024 | 2804 | 0.290 |
Why?
| | Mice | 21 | 2025 | 17787 | 0.290 |
Why?
| | Cell Line, Tumor | 10 | 2025 | 3412 | 0.290 |
Why?
| | Quinolines | 3 | 2025 | 178 | 0.290 |
Why?
| | Doxorubicin | 5 | 2020 | 362 | 0.290 |
Why?
| | Animals | 31 | 2025 | 36940 | 0.290 |
Why?
| | Neoplasms | 6 | 2022 | 2671 | 0.280 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2021 | 1396 | 0.280 |
Why?
| | Breast Neoplasms, Male | 2 | 2018 | 29 | 0.280 |
Why?
| | Employment | 2 | 2019 | 178 | 0.280 |
Why?
| | Kaplan-Meier Estimate | 4 | 2020 | 889 | 0.280 |
Why?
| | Cohort Studies | 11 | 2024 | 5742 | 0.270 |
Why?
| | Decision Making | 4 | 2022 | 900 | 0.270 |
Why?
| | Premenopause | 5 | 2025 | 131 | 0.260 |
Why?
| | Myeloid-Derived Suppressor Cells | 2 | 2018 | 66 | 0.260 |
Why?
| | Maytansine | 2 | 2018 | 16 | 0.260 |
Why?
| | Estrogen Receptor alpha | 3 | 2025 | 145 | 0.260 |
Why?
| | Adaptation, Psychological | 2 | 2022 | 655 | 0.250 |
Why?
| | Time Factors | 7 | 2020 | 6828 | 0.250 |
Why?
| | Disease Management | 3 | 2021 | 628 | 0.240 |
Why?
| | Estrogen Receptor Antagonists | 1 | 2025 | 3 | 0.240 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2011 | 622 | 0.240 |
Why?
| | Ovarian Reserve | 1 | 2025 | 16 | 0.240 |
Why?
| | Reproductive History | 2 | 2015 | 17 | 0.240 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2023 | 900 | 0.230 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2025 | 38 | 0.230 |
Why?
| | Macrophages | 4 | 2018 | 1547 | 0.230 |
Why?
| | Dimethyl Sulfoxide | 1 | 2005 | 41 | 0.230 |
Why?
| | Cell Plasticity | 1 | 2025 | 35 | 0.230 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1266 | 0.230 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 2 | 2022 | 95 | 0.230 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2025 | 165 | 0.220 |
Why?
| | Adolescent | 20 | 2024 | 21513 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 6 | 2024 | 2426 | 0.220 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 180 | 0.220 |
Why?
| | Bupropion | 1 | 2004 | 45 | 0.220 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2024 | 37 | 0.220 |
Why?
| | Disease Progression | 10 | 2020 | 2757 | 0.220 |
Why?
| | Lymph Nodes | 3 | 2019 | 491 | 0.210 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 786 | 0.210 |
Why?
| | Diarrhea | 3 | 2019 | 184 | 0.210 |
Why?
| | Immunotherapy | 3 | 2025 | 641 | 0.210 |
Why?
| | Disease Models, Animal | 5 | 2020 | 4295 | 0.200 |
Why?
| | Liver | 3 | 2020 | 1943 | 0.200 |
Why?
| | Cell Proliferation | 5 | 2021 | 2475 | 0.200 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 455 | 0.200 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2023 | 69 | 0.200 |
Why?
| | Age Factors | 9 | 2021 | 3295 | 0.200 |
Why?
| | Pharmaceutical Preparations | 1 | 2005 | 179 | 0.200 |
Why?
| | Treatment Outcome | 9 | 2025 | 10811 | 0.190 |
Why?
| | Aurora Kinase A | 2 | 2019 | 56 | 0.190 |
Why?
| | Genomic Instability | 1 | 2022 | 53 | 0.190 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2019 | 190 | 0.190 |
Why?
| | Chromatography, Liquid | 1 | 2004 | 433 | 0.190 |
Why?
| | Pilonidal Sinus | 1 | 2001 | 2 | 0.190 |
Why?
| | Follow-Up Studies | 4 | 2025 | 5131 | 0.190 |
Why?
| | Condylomata Acuminata | 1 | 2001 | 7 | 0.190 |
Why?
| | Proteomics | 2 | 2020 | 1111 | 0.190 |
Why?
| | Women's Health | 1 | 2024 | 372 | 0.180 |
Why?
| | Aged, 80 and over | 7 | 2025 | 7635 | 0.180 |
Why?
| | Hematopoiesis | 1 | 2022 | 192 | 0.180 |
Why?
| | Nausea | 2 | 2018 | 111 | 0.180 |
Why?
| | Retrospective Studies | 10 | 2025 | 15657 | 0.180 |
Why?
| | Ki-67 Antigen | 2 | 2019 | 112 | 0.170 |
Why?
| | Dyspareunia | 1 | 2020 | 8 | 0.170 |
Why?
| | Mass Spectrometry | 1 | 2004 | 739 | 0.170 |
Why?
| | Body Image | 3 | 2020 | 95 | 0.170 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 38 | 0.170 |
Why?
| | Mice, Inbred BALB C | 6 | 2019 | 1272 | 0.170 |
Why?
| | Tumor Microenvironment | 6 | 2021 | 674 | 0.170 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 1081 | 0.160 |
Why?
| | Ibuprofen | 2 | 2018 | 84 | 0.160 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.160 |
Why?
| | Risk | 3 | 2013 | 912 | 0.160 |
Why?
| | Biopsy | 4 | 2018 | 1129 | 0.160 |
Why?
| | Neoplasm Grading | 5 | 2021 | 307 | 0.160 |
Why?
| | Resistance Training | 1 | 2022 | 164 | 0.160 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 601 | 0.160 |
Why?
| | Parkinson Disease | 2 | 2015 | 493 | 0.160 |
Why?
| | Benzodiazepines | 1 | 2021 | 155 | 0.160 |
Why?
| | p21-Activated Kinases | 1 | 2019 | 15 | 0.160 |
Why?
| | Bone Neoplasms | 2 | 2016 | 247 | 0.160 |
Why?
| | Fatigue | 2 | 2018 | 329 | 0.160 |
Why?
| | Sexual Health | 1 | 2020 | 59 | 0.160 |
Why?
| | Cell Adhesion | 1 | 2020 | 466 | 0.150 |
Why?
| | Pyrazoles | 3 | 2018 | 423 | 0.150 |
Why?
| | Receptor, trkB | 1 | 2019 | 33 | 0.150 |
Why?
| | Immunohistochemistry | 8 | 2019 | 1738 | 0.150 |
Why?
| | Carcinoma, Ductal | 2 | 2011 | 11 | 0.150 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2019 | 34 | 0.150 |
Why?
| | Social Support | 3 | 2022 | 618 | 0.150 |
Why?
| | Cell Communication | 1 | 2020 | 315 | 0.150 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 18 | 0.150 |
Why?
| | Lymphangiogenesis | 2 | 2018 | 27 | 0.150 |
Why?
| | Germ Cells | 3 | 2024 | 64 | 0.150 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2018 | 14 | 0.150 |
Why?
| | Ipilimumab | 1 | 2018 | 33 | 0.150 |
Why?
| | Tryptophan Oxygenase | 1 | 2018 | 34 | 0.150 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2019 | 64 | 0.150 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 434 | 0.140 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2019 | 131 | 0.140 |
Why?
| | Progesterone | 2 | 2025 | 254 | 0.140 |
Why?
| | Parenting | 1 | 2022 | 310 | 0.140 |
Why?
| | Cisplatin | 1 | 2020 | 320 | 0.140 |
Why?
| | Area Under Curve | 1 | 2018 | 314 | 0.140 |
Why?
| | Vitamin D | 1 | 2021 | 397 | 0.140 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2018 | 385 | 0.140 |
Why?
| | Tretinoin | 1 | 2018 | 123 | 0.140 |
Why?
| | Immunity, Mucosal | 1 | 2018 | 97 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 249 | 0.130 |
Why?
| | Patient Care Management | 1 | 2017 | 57 | 0.130 |
Why?
| | Tryptophan | 1 | 2018 | 183 | 0.130 |
Why?
| | Granulocytes | 1 | 2017 | 80 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2023 | 718 | 0.130 |
Why?
| | Drug Delivery Systems | 2 | 2010 | 365 | 0.130 |
Why?
| | Case-Control Studies | 3 | 2020 | 3556 | 0.130 |
Why?
| | Socioeconomic Factors | 5 | 2021 | 1289 | 0.130 |
Why?
| | Global Health | 1 | 2020 | 386 | 0.130 |
Why?
| | Metaplasia | 1 | 2016 | 60 | 0.130 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 5778 | 0.130 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 434 | 0.130 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2016 | 35 | 0.130 |
Why?
| | Pancreatic Cyst | 1 | 2017 | 60 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2015 | 327 | 0.130 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 92 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2001 | 683 | 0.130 |
Why?
| | Genetic Testing | 2 | 2016 | 460 | 0.120 |
Why?
| | Mammography | 1 | 2017 | 154 | 0.120 |
Why?
| | Depression | 3 | 2020 | 1397 | 0.120 |
Why?
| | United States | 7 | 2024 | 14841 | 0.120 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 1995 | 12 | 0.120 |
Why?
| | Cellular Microenvironment | 1 | 2016 | 84 | 0.120 |
Why?
| | Antiparkinson Agents | 1 | 1995 | 27 | 0.120 |
Why?
| | Levodopa | 1 | 1995 | 30 | 0.120 |
Why?
| | Prostatic Neoplasms | 2 | 2021 | 1043 | 0.120 |
Why?
| | Epithelium | 2 | 2015 | 313 | 0.120 |
Why?
| | Transforming Growth Factor beta3 | 1 | 2015 | 10 | 0.120 |
Why?
| | Cytophagocytosis | 1 | 2015 | 8 | 0.120 |
Why?
| | Lung Neoplasms | 2 | 2021 | 2526 | 0.120 |
Why?
| | Prophylactic Surgical Procedures | 1 | 2015 | 7 | 0.120 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 350 | 0.120 |
Why?
| | Adherens Junctions | 1 | 2015 | 25 | 0.120 |
Why?
| | Chronic Pain | 1 | 2019 | 262 | 0.120 |
Why?
| | Paracrine Communication | 1 | 2015 | 65 | 0.120 |
Why?
| | Phosphoproteins | 2 | 2015 | 338 | 0.120 |
Why?
| | Menarche | 1 | 2015 | 60 | 0.110 |
Why?
| | Rats | 6 | 2021 | 5647 | 0.110 |
Why?
| | Hodgkin Disease | 1 | 2016 | 138 | 0.110 |
Why?
| | Cross-Sectional Studies | 6 | 2022 | 5472 | 0.110 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 220 | 0.110 |
Why?
| | Aging | 1 | 2025 | 1864 | 0.110 |
Why?
| | Lymphocyte Activation | 3 | 2017 | 1142 | 0.110 |
Why?
| | Pyrimidines | 1 | 2018 | 470 | 0.110 |
Why?
| | Spleen | 1 | 2017 | 514 | 0.110 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 697 | 0.110 |
Why?
| | Lymph Node Excision | 2 | 2021 | 171 | 0.110 |
Why?
| | Microfilament Proteins | 1 | 2015 | 133 | 0.110 |
Why?
| | Survival Analysis | 4 | 2021 | 1325 | 0.110 |
Why?
| | Pregnancy Outcome | 3 | 2023 | 416 | 0.110 |
Why?
| | Survivors | 3 | 2023 | 493 | 0.110 |
Why?
| | Extracellular Matrix | 2 | 2016 | 528 | 0.110 |
Why?
| | Administration, Oral | 3 | 2025 | 816 | 0.110 |
Why?
| | Genes, BRCA2 | 2 | 2015 | 31 | 0.110 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2014 | 33 | 0.110 |
Why?
| | Amenorrhea | 1 | 2014 | 31 | 0.110 |
Why?
| | Genes, BRCA1 | 2 | 2015 | 40 | 0.110 |
Why?
| | Odds Ratio | 4 | 2020 | 1070 | 0.110 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 218 | 0.110 |
Why?
| | Carbon Cycle | 1 | 2014 | 18 | 0.110 |
Why?
| | Brain Edema | 1 | 2014 | 61 | 0.110 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1509 | 0.110 |
Why?
| | Male | 20 | 2022 | 67762 | 0.110 |
Why?
| | Monocytes | 1 | 2017 | 563 | 0.110 |
Why?
| | Collagen | 2 | 2021 | 452 | 0.110 |
Why?
| | Spouses | 1 | 2015 | 105 | 0.110 |
Why?
| | Tremor | 1 | 1994 | 65 | 0.110 |
Why?
| | Disability Evaluation | 1 | 2015 | 290 | 0.110 |
Why?
| | Droughts | 1 | 2014 | 44 | 0.100 |
Why?
| | Astrocytes | 1 | 2015 | 210 | 0.100 |
Why?
| | Signal Transduction | 4 | 2020 | 5079 | 0.100 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2016 | 80 | 0.100 |
Why?
| | Nitriles | 1 | 2014 | 172 | 0.100 |
Why?
| | Atmosphere | 1 | 2014 | 87 | 0.100 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 3 | 2019 | 61 | 0.100 |
Why?
| | Infertility, Female | 1 | 2014 | 108 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 976 | 0.100 |
Why?
| | Triazoles | 1 | 2014 | 147 | 0.100 |
Why?
| | Trans-Activators | 1 | 2015 | 398 | 0.100 |
Why?
| | Postural Balance | 1 | 2015 | 215 | 0.100 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 27 | 0.100 |
Why?
| | Lymphatic Vessels | 3 | 2019 | 64 | 0.100 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 1000 | 0.100 |
Why?
| | Myeloid Cells | 1 | 2013 | 148 | 0.100 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1431 | 0.100 |
Why?
| | Drug Design | 1 | 2013 | 167 | 0.090 |
Why?
| | Live Birth | 2 | 2023 | 66 | 0.090 |
Why?
| | Logistic Models | 5 | 2016 | 2074 | 0.090 |
Why?
| | Genes, Bacterial | 1 | 2012 | 164 | 0.090 |
Why?
| | Mice, Inbred C57BL | 6 | 2019 | 5757 | 0.090 |
Why?
| | Wound Healing | 1 | 2014 | 331 | 0.090 |
Why?
| | Apoptosis | 3 | 2019 | 2553 | 0.090 |
Why?
| | Fibrillar Collagens | 1 | 2011 | 13 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2015 | 397 | 0.090 |
Why?
| | Transcriptome | 2 | 2021 | 971 | 0.090 |
Why?
| | Double-Blind Method | 3 | 2021 | 1993 | 0.090 |
Why?
| | Patient Participation | 1 | 2015 | 420 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 346 | 0.090 |
Why?
| | Streptococcus agalactiae | 1 | 2012 | 93 | 0.090 |
Why?
| | Membrane Proteins | 2 | 2015 | 1164 | 0.090 |
Why?
| | Antigen Presentation | 2 | 2018 | 218 | 0.090 |
Why?
| | Biopsy, Needle | 1 | 2011 | 189 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 872 | 0.080 |
Why?
| | Estrogen Antagonists | 1 | 2010 | 45 | 0.080 |
Why?
| | Adenocarcinoma | 2 | 2015 | 940 | 0.080 |
Why?
| | Sexual Behavior | 1 | 2014 | 485 | 0.080 |
Why?
| | Cell Fusion | 2 | 2006 | 51 | 0.080 |
Why?
| | Clinical Trials as Topic | 3 | 2017 | 1050 | 0.080 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 80 | 0.080 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2021 | 220 | 0.080 |
Why?
| | Mucin-1 | 1 | 2009 | 21 | 0.080 |
Why?
| | Cell Movement | 3 | 2019 | 967 | 0.080 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2021 | 115 | 0.080 |
Why?
| | Reference Standards | 2 | 2012 | 186 | 0.080 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.080 |
Why?
| | Drug Monitoring | 1 | 2010 | 218 | 0.080 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 18 | 0.080 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2019 | 317 | 0.070 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 140 | 0.070 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 188 | 0.070 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2020 | 50 | 0.070 |
Why?
| | Macrophage Activation | 1 | 2010 | 201 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 4 | 2016 | 2486 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 2057 | 0.070 |
Why?
| | Interferon-beta | 1 | 2008 | 92 | 0.070 |
Why?
| | Metalloproteases | 1 | 2008 | 43 | 0.070 |
Why?
| | Extracellular Matrix Proteins | 1 | 2009 | 153 | 0.070 |
Why?
| | Sensitivity and Specificity | 3 | 2013 | 1946 | 0.070 |
Why?
| | Gonadal Steroid Hormones | 1 | 2009 | 140 | 0.070 |
Why?
| | Age of Onset | 2 | 2021 | 518 | 0.070 |
Why?
| | Cell Cycle | 2 | 2021 | 601 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2009 | 382 | 0.070 |
Why?
| | Genomics | 2 | 2023 | 795 | 0.070 |
Why?
| | Maximum Tolerated Dose | 2 | 2018 | 199 | 0.070 |
Why?
| | Disease Susceptibility | 1 | 2009 | 347 | 0.070 |
Why?
| | ErbB Receptors | 3 | 2017 | 614 | 0.070 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 327 | 0.070 |
Why?
| | HIV Infections | 1 | 2001 | 2836 | 0.070 |
Why?
| | Antibodies, Monoclonal | 3 | 2009 | 1430 | 0.060 |
Why?
| | Sternum | 1 | 2006 | 24 | 0.060 |
Why?
| | Mice, Nude | 3 | 2015 | 698 | 0.060 |
Why?
| | Cell Survival | 2 | 2020 | 1120 | 0.060 |
Why?
| | Postmenopause | 2 | 2005 | 366 | 0.060 |
Why?
| | Membrane Glycoproteins | 2 | 2019 | 500 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1062 | 0.060 |
Why?
| | Ovariectomy | 2 | 2019 | 152 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2019 | 4193 | 0.060 |
Why?
| | Axilla | 2 | 2021 | 47 | 0.060 |
Why?
| | Mammaplasty | 2 | 2021 | 105 | 0.060 |
Why?
| | Child | 6 | 2022 | 21935 | 0.060 |
Why?
| | Forkhead Transcription Factors | 2 | 2018 | 191 | 0.060 |
Why?
| | Models, Biological | 2 | 2012 | 1783 | 0.060 |
Why?
| | Fear | 2 | 2021 | 338 | 0.060 |
Why?
| | Prolactin | 1 | 2025 | 96 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2025 | 3015 | 0.060 |
Why?
| | Anti-Mullerian Hormone | 1 | 2025 | 57 | 0.060 |
Why?
| | Infant, Newborn | 2 | 2023 | 6079 | 0.060 |
Why?
| | Thyrotropin | 1 | 2025 | 114 | 0.060 |
Why?
| | Dendritic Cells | 2 | 2005 | 483 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 840 | 0.060 |
Why?
| | Solubility | 1 | 2005 | 245 | 0.060 |
Why?
| | Analysis of Variance | 3 | 2014 | 1316 | 0.050 |
Why?
| | Ovulation Induction | 1 | 2024 | 56 | 0.050 |
Why?
| | Neoplastic Processes | 1 | 2023 | 4 | 0.050 |
Why?
| | Follicle Stimulating Hormone | 1 | 2025 | 244 | 0.050 |
Why?
| | Weaning | 2 | 2016 | 47 | 0.050 |
Why?
| | Cancer Vaccines | 1 | 2005 | 172 | 0.050 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2025 | 209 | 0.050 |
Why?
| | North America | 1 | 2024 | 313 | 0.050 |
Why?
| | Cryopreservation | 1 | 2024 | 100 | 0.050 |
Why?
| | Celecoxib | 2 | 2014 | 39 | 0.050 |
Why?
| | Peptide YY | 1 | 2022 | 17 | 0.050 |
Why?
| | Ghrelin | 1 | 2022 | 36 | 0.050 |
Why?
| | Withholding Treatment | 1 | 2023 | 76 | 0.050 |
Why?
| | DNA End-Joining Repair | 1 | 2022 | 20 | 0.050 |
Why?
| | Sensation | 1 | 2022 | 53 | 0.050 |
Why?
| | Peptides | 1 | 2008 | 985 | 0.050 |
Why?
| | Appetite | 1 | 2022 | 69 | 0.050 |
Why?
| | Mucins | 1 | 2022 | 73 | 0.050 |
Why?
| | Cost of Illness | 1 | 2024 | 308 | 0.050 |
Why?
| | Multiple Myeloma | 1 | 2005 | 252 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 156 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 336 | 0.050 |
Why?
| | Heterozygote | 1 | 2022 | 293 | 0.050 |
Why?
| | Colorado | 3 | 2020 | 4565 | 0.050 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2021 | 43 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2007 | 786 | 0.050 |
Why?
| | Genes, p53 | 1 | 2021 | 72 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2015 | 547 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 106 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2012 | 3284 | 0.040 |
Why?
| | Placebos | 1 | 2021 | 199 | 0.040 |
Why?
| | Hypertrophy | 1 | 2021 | 133 | 0.040 |
Why?
| | In Situ Hybridization | 1 | 2001 | 316 | 0.040 |
Why?
| | Protective Agents | 1 | 2021 | 41 | 0.040 |
Why?
| | Immunity | 1 | 2021 | 143 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2021 | 133 | 0.040 |
Why?
| | DNA Replication | 1 | 2022 | 238 | 0.040 |
Why?
| | Hormones | 1 | 2021 | 143 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2019 | 1091 | 0.040 |
Why?
| | DNA Repair | 1 | 2022 | 231 | 0.040 |
Why?
| | Pregnancy Rate | 1 | 2020 | 65 | 0.040 |
Why?
| | Hospitals, University | 1 | 2021 | 182 | 0.040 |
Why?
| | Arm | 1 | 2021 | 104 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 402 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2022 | 564 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 310 | 0.040 |
Why?
| | Flow Cytometry | 3 | 2013 | 1178 | 0.040 |
Why?
| | Consolidation Chemotherapy | 1 | 2019 | 10 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 324 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2020 | 329 | 0.040 |
Why?
| | SEER Program | 1 | 2021 | 227 | 0.040 |
Why?
| | Age Distribution | 1 | 2020 | 392 | 0.040 |
Why?
| | Energy Intake | 1 | 2022 | 485 | 0.040 |
Why?
| | Kidney Neoplasms | 1 | 2004 | 403 | 0.040 |
Why?
| | Terminology as Topic | 1 | 2021 | 216 | 0.040 |
Why?
| | DNA, Viral | 1 | 2001 | 364 | 0.040 |
Why?
| | Fibronectins | 1 | 2020 | 133 | 0.040 |
Why?
| | Unemployment | 1 | 2019 | 43 | 0.040 |
Why?
| | Vaginal Diseases | 1 | 2019 | 21 | 0.040 |
Why?
| | Base Sequence | 2 | 2016 | 2181 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2828 | 0.040 |
Why?
| | Sulfonamides | 2 | 2014 | 513 | 0.040 |
Why?
| | Leuprolide | 1 | 2019 | 20 | 0.040 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2019 | 68 | 0.040 |
Why?
| | Interleukin-10 | 2 | 2014 | 302 | 0.040 |
Why?
| | Weight Gain | 1 | 2022 | 519 | 0.040 |
Why?
| | Crosses, Genetic | 1 | 2018 | 137 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2018 | 35 | 0.040 |
Why?
| | Hot Flashes | 1 | 2019 | 87 | 0.040 |
Why?
| | Factor Analysis, Statistical | 1 | 2019 | 283 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2019 | 139 | 0.040 |
Why?
| | Integrins | 1 | 2018 | 95 | 0.040 |
Why?
| | Body Weight | 1 | 2022 | 985 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 94 | 0.040 |
Why?
| | Phenotype | 2 | 2020 | 3196 | 0.030 |
Why?
| | Kynurenine | 1 | 2018 | 114 | 0.030 |
Why?
| | Contraceptives, Oral | 1 | 2017 | 43 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2020 | 622 | 0.030 |
Why?
| | Behavior | 1 | 2018 | 90 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2021 | 660 | 0.030 |
Why?
| | B7-H1 Antigen | 1 | 2019 | 217 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2021 | 561 | 0.030 |
Why?
| | Educational Status | 1 | 2019 | 470 | 0.030 |
Why?
| | Tumor Escape | 1 | 2017 | 42 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 787 | 0.030 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 210 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2016 | 49 | 0.030 |
Why?
| | Emulsions | 1 | 2016 | 53 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 324 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1066 | 0.030 |
Why?
| | Alleles | 1 | 2019 | 891 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 847 | 0.030 |
Why?
| | Risk Assessment | 2 | 2020 | 3457 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2018 | 363 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 268 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 482 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 318 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 130 | 0.030 |
Why?
| | Antigens, Differentiation | 1 | 2015 | 83 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1477 | 0.030 |
Why?
| | Medication Adherence | 1 | 2019 | 467 | 0.030 |
Why?
| | Body Mass Index | 2 | 2015 | 2389 | 0.030 |
Why?
| | Medicare | 1 | 2021 | 773 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 411 | 0.030 |
Why?
| | Directive Counseling | 1 | 2015 | 47 | 0.030 |
Why?
| | Hybrid Cells | 2 | 2005 | 49 | 0.030 |
Why?
| | Biomarkers | 2 | 2021 | 4149 | 0.030 |
Why?
| | Reproduction | 1 | 2016 | 204 | 0.030 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2015 | 80 | 0.030 |
Why?
| | Cognition | 1 | 2022 | 1153 | 0.030 |
Why?
| | Terminal Care | 1 | 2018 | 232 | 0.030 |
Why?
| | Posture | 1 | 2015 | 185 | 0.030 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 250 | 0.030 |
Why?
| | Tropical Climate | 1 | 2014 | 19 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 322 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 2014 | 87 | 0.030 |
Why?
| | Genotype | 1 | 2019 | 1916 | 0.030 |
Why?
| | Biota | 1 | 2014 | 34 | 0.030 |
Why?
| | Tumor Burden | 1 | 2015 | 309 | 0.030 |
Why?
| | Dinoprostone | 1 | 2014 | 191 | 0.030 |
Why?
| | Fresh Water | 1 | 2014 | 57 | 0.030 |
Why?
| | STAT5 Transcription Factor | 1 | 2013 | 57 | 0.030 |
Why?
| | Carbon Monoxide | 1 | 2014 | 81 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2013 | 55 | 0.030 |
Why?
| | Brazil | 1 | 2014 | 167 | 0.030 |
Why?
| | Biomass | 1 | 2014 | 118 | 0.030 |
Why?
| | Dermoscopy | 1 | 2013 | 10 | 0.030 |
Why?
| | Trees | 1 | 2014 | 71 | 0.030 |
Why?
| | Rain | 1 | 2014 | 47 | 0.030 |
Why?
| | Massachusetts | 1 | 2014 | 172 | 0.030 |
Why?
| | Child, Preschool | 2 | 2021 | 11074 | 0.030 |
Why?
| | Immunoblotting | 1 | 2014 | 308 | 0.030 |
Why?
| | Necrosis | 1 | 2014 | 246 | 0.030 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 192 | 0.030 |
Why?
| | Oncogenes | 1 | 2013 | 116 | 0.030 |
Why?
| | Family Health | 1 | 1994 | 196 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 85 | 0.030 |
Why?
| | beta Catenin | 1 | 2015 | 253 | 0.030 |
Why?
| | Photosynthesis | 1 | 2014 | 104 | 0.030 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 515 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2018 | 785 | 0.030 |
Why?
| | Karyotyping | 1 | 2012 | 104 | 0.020 |
Why?
| | Accidental Falls | 1 | 2015 | 196 | 0.020 |
Why?
| | Fires | 1 | 2014 | 89 | 0.020 |
Why?
| | Immune System | 1 | 2014 | 177 | 0.020 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2014 | 212 | 0.020 |
Why?
| | Adiposity | 1 | 2017 | 518 | 0.020 |
Why?
| | Observer Variation | 1 | 2013 | 343 | 0.020 |
Why?
| | Menopause | 1 | 2015 | 320 | 0.020 |
Why?
| | Carcinogenesis | 1 | 2013 | 217 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1622 | 0.020 |
Why?
| | Cell Division | 1 | 2013 | 794 | 0.020 |
Why?
| | Calibration | 1 | 2012 | 146 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1060 | 0.020 |
Why?
| | Carbon Dioxide | 1 | 2014 | 267 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2189 | 0.020 |
Why?
| | Interferon-gamma | 2 | 2005 | 789 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 2691 | 0.020 |
Why?
| | Seasons | 1 | 2014 | 547 | 0.020 |
Why?
| | RNA, Bacterial | 1 | 2012 | 190 | 0.020 |
Why?
| | Palliative Care | 1 | 2018 | 758 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2018 | 1991 | 0.020 |
Why?
| | Mice, SCID | 1 | 2011 | 367 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2847 | 0.020 |
Why?
| | Genome, Human | 1 | 2013 | 425 | 0.020 |
Why?
| | Self Report | 1 | 2015 | 827 | 0.020 |
Why?
| | Photochemotherapy | 1 | 2010 | 44 | 0.020 |
Why?
| | Universities | 1 | 2013 | 433 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 956 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2012 | 328 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 325 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1972 | 0.020 |
Why?
| | Matrix Metalloproteinases | 1 | 2010 | 95 | 0.020 |
Why?
| | Physician-Patient Relations | 1 | 2014 | 548 | 0.020 |
Why?
| | Keratin-19 | 1 | 2009 | 3 | 0.020 |
Why?
| | Immunomagnetic Separation | 1 | 2009 | 5 | 0.020 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 20 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1295 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2009 | 82 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1483 | 0.020 |
Why?
| | Vinblastine | 1 | 2009 | 71 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1226 | 0.020 |
Why?
| | Species Specificity | 1 | 2010 | 585 | 0.020 |
Why?
| | ADAM12 Protein | 1 | 2008 | 4 | 0.020 |
Why?
| | Flavonoids | 1 | 2009 | 85 | 0.020 |
Why?
| | Perilipin-1 | 1 | 2008 | 17 | 0.020 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 17 | 0.020 |
Why?
| | S100 Proteins | 1 | 2008 | 37 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2009 | 115 | 0.020 |
Why?
| | Sex Factors | 1 | 1994 | 2071 | 0.020 |
Why?
| | ADAM Proteins | 1 | 2008 | 61 | 0.020 |
Why?
| | Perimenopause | 1 | 2008 | 63 | 0.020 |
Why?
| | DNA Primers | 1 | 2009 | 515 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 107 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2008 | 132 | 0.020 |
Why?
| | Radiotherapy | 1 | 2008 | 201 | 0.020 |
Why?
| | Prevalence | 1 | 2014 | 2734 | 0.020 |
Why?
| | Piperidines | 1 | 2009 | 206 | 0.020 |
Why?
| | Gene Expression | 1 | 2012 | 1502 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 530 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2008 | 169 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2008 | 499 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 861 | 0.020 |
Why?
| | Pleural Effusion | 1 | 2006 | 54 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 767 | 0.020 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2005 | 50 | 0.010 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2005 | 41 | 0.010 |
Why?
| | Receptors, CCR7 | 1 | 2005 | 32 | 0.010 |
Why?
| | Receptors, Chemokine | 1 | 2005 | 47 | 0.010 |
Why?
| | Antigens, CD34 | 1 | 2005 | 88 | 0.010 |
Why?
| | Interleukin-12 | 1 | 2005 | 121 | 0.010 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 294 | 0.010 |
Why?
| | Hemocyanins | 1 | 2004 | 62 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2012 | 1100 | 0.010 |
Why?
| | Patient Care Planning | 1 | 2005 | 157 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2004 | 239 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 771 | 0.010 |
Why?
| | Cell Separation | 1 | 2004 | 318 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2006 | 620 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2004 | 955 | 0.010 |
Why?
| | Brain | 1 | 2014 | 2668 | 0.010 |
Why?
| | Paclitaxel | 1 | 2003 | 230 | 0.010 |
Why?
| | Pilot Projects | 1 | 2003 | 1710 | 0.010 |
Why?
| | Vaccination | 1 | 2004 | 1381 | 0.010 |
Why?
|
|
Borges's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|